Provid Pharmaceuticals to Support Drug Discovery for Palatin Technologies
Posted on: Monday, 17 October 2005, 12:00 CDT
NORTH BRUNSWICK, N.J., Oct. 17 /PRNewswire/ -- Provid Pharmaceuticals Inc. of North Brunswick, NJ, entered into a research services agreement with Palatin Technologies of Cranbury, NJ for the optimization of leads emerging from Palatin's Proprietary MIDAS(TM) novel drug discovery technology.
Provid will employ its expertise in peptide mimetics technology, computational modeling, and medicinal chemistry to optimize research drug candidates that were identified using Palatin's MIDAS(TM) technology. "We are pleased to be complementing the efforts of Palatin in drug discovery chemistry for these important therapeutic targets," commented Dr. Gary Olson, President and CEO of Provid.
"We are very pleased to have the Provid team working with Palatin to transform our exciting leads into drug candidates. Provid's experience in all aspects of medicinal chemistry is going to be a key factor in the acceleration of our internal drug pipeline," said Dr. Trevor Hallam, Executive Vice- President of R&D of Palatin. Financial terms of the agreement were not disclosed.
Provid Pharmaceuticals Inc. is a drug discovery company engaged in the identification of novel lead compounds for pharmaceutical development and providing expert collaborative research services to the biotech and pharmaceutical industries. Provid offers capabilities in medicinal chemistry, structure-based drug design, and lead optimization, as well as protein biochemistry and assay development. Provid is also recognized as a world leader in peptide mimetics technology. In addition to collaborations, Provid has ongoing internal programs in autoimmune disease therapeutics, targeting multiple sclerosis, rheumatoid arthritis, and celiac disease. For more information visit: http://www.providpharma.com/.
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 regarding Provid's future activities and the potential for discovery of drug compounds, and involve a high degree of material risks and uncertainties. Many possible factors could affect future results and performance of Provid's research and development activities, and ability to develop pharmaceuticals based on the company's technology and the Palatin targets. If Provid's efforts fail to perform as expected, or if any of a wide range of other risk factors are encountered and not surmounted, the company's financial condition and operating results may be materially and adversely effected.
For more information, contact: Edwin Thomas, COO Provid Pharmaceuticals Inc. 732-565-1101 x 620 edwin.thomas@providpharma.com
Provid Pharmaceuticals Inc.
CONTACT: Edwin Thomas, COO, Provid Pharmaceuticals Inc., +1-732-565-1101x620, edwin.thomas@providpharma.com
Web site: http://www.providpharma.com/
Source: PRNewswire
Related Articles
- Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research
- New Biopharma Company Appian Labs, LLC Provides Drug Design and Delivery Solutions
- Shot in the Arm: South Korean Government Promises a Hike in Drug and Pharmaceutical R&D Expenditure
- Key Research on Cancer Stem Cells and Their Relevance and Impact on Drug and Diagnostic Discovery
- Social Networks Impact the Drugs Physicians Prescribe According to Stanford Business School Research
- Provid to Acquire Tripos Discovery Research
- Zimbabwe Fails to Meet WHO Target of Providing Drugs to AIDS Patients
- The U.S. Food and Drug Administration Will Use GeneGo's MetaCore for 'OMIC's' Research and Reviewing of Genomics Data
- Procter & Gamble Selects Evotec As Provider of Pharmaceutical Discovery and Chemical Development Services
- 2 Americans win Nobel for chemistry research
 |
 |
User Comments (0)
RSS Feeds